country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P990033

Copy Link Print Information

Biologically Validated

Anzurstobart

(別名: CC-95251; BMS-986351)

カスタマーレビュー

Based on 1 Customer Validation

Anzurstobart (CC-95251; BMS-986351) is a CD47/SIRPα inhibitor with human SIRPα K_d of 0.0541 nM and human SIRPα IC₅₀ of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.0%
CAS 番号: 2543693-10-1
分子量:144.66 kDa

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Anzurstobart 構造式

CAS 番号: 2543693-10-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- 体外実験
- Parmacokinetics
- 体内実験
- 臨床実験
- 遺伝子ID
- アクセッション番号
- Conjugated
- Reconsititution
- Format
- アプリケーション
- Verified Bioactivity
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

SIRPa/CD172a

体外実験

Anzurstobart (CC-95251) potently blocks CD47-SIRPα binding in a dose-dependent manner, with near-complete inhibition at 100 nM^[1].
Anzurstobart (50 nM; 180 seconds) demonstrates strong binding coverage across the six most prevalent human SIRPα haplotypes^[1].
Anzurstobart (20 nmol/L; 10 minutes preincubation, 3-hour coculture) alone dose-dependently increases macrophage-mediated phagocytosis of GP2d, GP5d, and SW480 colorectal cancer cells^[1].
Anzurstobart (20 nmol/L; 10 minutes preincubation, 3-hour coculture) in combination with Rituximab (HY-P9913) dose-dependently enhances macrophage-mediated phagocytosis of OCI-Ly3, RIVA, Pfeiffer, and Karpas 422 DLBCL cells, while Anzurstobart alone has limited phagocytic activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_max	C_max	T_1/2	CL	V_dss
Cynomolgus Monkey^[2]	10 mg/kg	i.v.	1.50 h	183 μg/mL	227 h	186.48 mL/h/kg	99.80 mL/kg
Cynomolgus Monkey^[2]	30 mg/kg	i.v.	0.25 h	632 μg/mL	185 h	206.16 mL/h/kg	80.47 mL/kg
Cynomolgus Monkey^[2]	100 mg/kg	i.v.	1.50 h	1,984 μg/mL	217 h	200.88 mL/h/kg	91.93 mL/kg

体内実験

Anzurstobart (CC-95251) (10-100 mg/kg; i.v.; single dose, repeat dose) results in dose-dependent peak serum concentrations, a half-life of 163-227 hours, and no hematologic cell depletion over 28 days in Macaca fascicularis^[1].
Anzurstobart (10-100 mg/kg; i.v.) is well-tolerated in healthy cynomolgus monkeys with no hematologic depletion observed^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Cynomolgus monkeys^[2]
Dosage:

10 mg/kg; 30 mg/kg; 100 mg/kg
Administration:

i.v.; single dose (day 1); repeat dose (day 15)
Result:

Reached peak serum concentrations (Cmax) of 183 μg/mL (10 mg/kg), 632 μg/mL (30 mg/kg), and 1984 μg/mL (100 mg/kg) after day 1 dose.
Reached peak serum concentrations (Cmax) of 183 μg/mL (10 mg/kg), 664 μg/mL (30 mg/kg), and 2276 μg/mL (100 mg/kg) after day 15 dose.
Exhibited half-life (T1/2) ranging from 163 to 227 hours across individual animals.
Showed clearance rates ranging from 7.77 to 15.48 mL/day/kg.
Caused no depletion of white blood cells, monocytes, lymphocytes, or red blood cells over 28 days of exposure.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

遺伝子ID

140885 [NCBI]

アクセッション番号

P78324

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

アプリケーション

ELISA, FACS, Functional assay

Verified Bioactivity

Flow Cytometry analysis of U937 cells labelling SIRPa/CD172a (red) with Anzurstobart (anti-SIRPa/CD172a) (HY-P990033). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

化学情報

CAS 番号 2543693-10-1
性状 Liquid
分子量 144.66 kDa
Color Colorless to light yellow
SMILES

[Anzurstobart]
別名

CC-95251; BMS-986351
輸送条件

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (262 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

参考文献

[1]. Chan H, et al. Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies. Cancer Res Commun. 2024;4(2):505-515. [Content Brief]

[2]. Chan H, et al. Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab. Blood. 2021;2271-2272.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- 体外実験
- 体内実験
- 臨床実験
- 遺伝子ID
- アクセッション番号
- Conjugated
- Reconsititution
- Format
- アプリケーション
- Biological Activity
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Anzurstobart

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

Cytotoxicity LDH Assay Kit

DPBS Buffer (1×)

Antibody Inhibitor Library

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Anzurstobart 関連分類

HY-P990033 関連分類